Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX

Rheumatology (United Kingdom)

Volumn 51, Issue 7, 2012, Pages 1226-1234

  Choy, Ernest ^a   Mckenna, Frank ^b   Vencovsky, Jiri ^c   Valente, Robert ^d   Goel, Niti ^e   Vanlunen, Brenda ^e   Davies, Owen ^e   Stahl, Hans Detlev ^f   Alten, Rieke ^g  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b TRAFFORD GENERAL HOSPITAL   (United Kingdom)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Arthritis Center of Nebraska   (United States)

^e UCB PHARMA   (Belgium)

^f Synexus ClinPharm GmbH   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ACR20; Anti TNF; Certolizumab pegol; DAS28 3; Methotrexate; Rheumatoid arthritis

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; CELLULITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEMALE; HEADACHE; HERPES SIMPLEX; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MENINGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SINUSITIS; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOLOGIC FACTORS; MALE; METHOTREXATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863854575     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker519     Document Type: Article

References (15)

1. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
2. Keystone E, van der Heijde D, Mason D et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
3. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
4. Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
5. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
6. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
7. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
8. Fleischmann R, Vencovsky J, van Vollenhoven R et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68: 805-11.
9. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727-35.
10. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
11. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25:206-9.
12. Ware JE, Snow KK, Kosinski M et al. SF-36 health survey manual and interpretation guide. Boston, MA: New England Medical Center Health Institute, 1993.
13. Ware JE, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: New England Medical Center Health Institute, 1994.
14. Lacroix BD, Lovern MR, Stockis A et al. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther 2009;86:387-95.
15. Guyatt GH, Townsend M, Berman LB et al. A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 1987;40:1129-33.